These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32125077)

  • 1. Multivariate network meta-analysis of survival function parameters.
    Cope S; Chan K; Jansen JP
    Res Synth Methods; 2020 May; 11(3):443-456. PubMed ID: 32125077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.
    Cope S; Chan K; Campbell H; Chen J; Borrill J; May JR; Malcolm W; Branchoux S; Kupas K; Jansen JP
    Value Health; 2023 Apr; 26(4):465-476. PubMed ID: 36503035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making.
    Cope S; Jansen JP
    BMC Med Res Methodol; 2013 Dec; 13():147. PubMed ID: 24289277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
    Cope S; Ouwens MJ; Jansen JP; Schmid P
    Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network.
    Freeman SC; Cooper NJ; Sutton AJ; Crowther MJ; Carpenter JR; Hawkins N
    Stat Methods Med Res; 2022 May; 31(5):839-861. PubMed ID: 35044255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data.
    Watkins C; Bennett I
    Res Synth Methods; 2018 Sep; 9(3):352-360. PubMed ID: 29707913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parametric modeling of localized melanoma prognosis and outcome.
    Ding S; Soong SJ; Lin HY; Desmond R; Balch CM
    J Biopharm Stat; 2009 Jul; 19(4):732-47. PubMed ID: 20183437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A design-by-treatment interaction model for network meta-analysis and meta-regression with integrated nested Laplace approximations.
    Günhan BK; Friede T; Held L
    Res Synth Methods; 2018 Jun; 9(2):179-194. PubMed ID: 29193801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exponentiated Weibull regression for time-to-event data.
    Khan SA
    Lifetime Data Anal; 2018 Apr; 24(2):328-354. PubMed ID: 28349290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis.
    Wiksten A; Hawkins N; Piepho HP; Gsteiger S
    Value Health; 2020 Jul; 23(7):918-927. PubMed ID: 32762994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes.
    Jansen JP; Cope S
    BMC Med Res Methodol; 2012 Oct; 12():152. PubMed ID: 23043545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models.
    Freeman SC; Carpenter JR
    Res Synth Methods; 2017 Dec; 8(4):451-464. PubMed ID: 28742955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of time-to-event data using a flexible mixture model under a constraint of proportional hazards.
    Liu GF; Liao JJZ
    J Biopharm Stat; 2020 Sep; 30(5):783-796. PubMed ID: 32589509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging Cumulative Network Meta-analysis and Value of Information Analysis to Understand the Evolving Value of Medical Research.
    Kim DD; Trikalinos TA; Wong JB
    Med Decis Making; 2019 Feb; 39(2):119-129. PubMed ID: 30678537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival time prediction by integrating cox proportional hazards network and distribution function network.
    Baek ET; Yang HJ; Kim SH; Lee GS; Oh IJ; Kang SR; Min JJ
    BMC Bioinformatics; 2021 Apr; 22(1):192. PubMed ID: 33858319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
    Phadnis MA; Mayo MS
    Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penalized Poisson model for network meta-analysis of individual patient time-to-event data.
    Ollier E; Blanchard P; Le Teuff G; Michiels S
    Stat Med; 2022 Jan; 41(2):340-355. PubMed ID: 34710951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-stage parametric meta-analysis of time-to-event outcomes.
    Siannis F; Barrett JK; Farewell VT; Tierney JF
    Stat Med; 2010 Dec; 29(29):3030-45. PubMed ID: 20963770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
    Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
    Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.